When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2 screening program in partnership with the CSIRO and the University of Melbourne’s Doherty Institute back in July, the news threatened to overshadow some of the other pioneering work being undertaken by the health company.
Related Post
Prescient Therapeutics AGM 2024
November 18, 2024